急诊就诊COVID-19患者生物标志物水平与胸部影像的预后价值
该回顾性病历回顾研究纳入2020年2月至12月在一家三级医疗中心急诊就诊、≥18岁、COVID-19实时逆转录聚合酶链反应阳性且就诊时接受CT检查的患者,比较定量CT严重程度评分与C反应蛋白、降钙素原、中性粒细胞/淋巴细胞比值、D-二聚体、铁蛋白、乳酸脱氢酶、乳酸、肌钙蛋白和B型利钠肽预测院内死亡的价值。主要结局为CT严重程度评分与生物标志物预测院内死亡的预后能力,D-二聚体AUC为0.67(95%CI 0.57-0.77)、CT严重程度评分为0.66(95%CI 0.55-0.77)、LDH为0.66(95%CI 0.55-0.77)。逐步logistic回归中,年龄(OR=1.07,95%CI 1.05-1.09)、肥胖(OR=2.02,95%CI 1.25-3.26)、中性粒细胞/淋巴细胞比值(OR=1.02,95%CI 1.01-1.04)、CRP(OR=1.01,95%CI 1.004-1.01)、乳酸脱氢酶(OR=1.003,95%CI 1.001-1.004)和CT严重程度评分(OR=1.17,95%CI 1.12-1.23)与院内死亡显著相关。作者结论认为CT严重程度评分作为COVID相关死亡的预后工具优于多种生物标志物。
要点
- 在急诊COVID-19患者中,D-二聚体预测院内死亡的AUC为0.67(95%CI 0.57-0.77),CT严重程度评分为0.66(95%CI 0.55-0.77),LDH为0.66(95%CI 0.55-0.77)。
- 逐步logistic回归显示,CT严重程度评分与院内死亡显著相关(OR=1.17,95%CI 1.12-1.23),年龄(OR=1.07,95%CI 1.05-1.09)和肥胖(OR=2.02,95%CI 1.25-3.26)亦为显著相关因素。
- 作者建议,对需要肺部影像的COVID-19患者(如需要ICU入住、生命体征异常和需要机械通气的患者),获取并计算CT严重程度评分作为预后工具。
- 作者建议,若未进行CT检查,可使用已完成的LDH、CRP或NLR作为COVID-19的预后工具,因为这些生物标志物也被发现具有预后价值。
适用人群与场景
- 2020年2月至12月期间就诊于一家三级医疗中心急诊、≥18岁、COVID-19实时逆转录聚合酶链反应阳性且就诊时接受CT成像的患者。
研究设计与关键结果
- 研究类型为回顾性病历回顾研究,纳入2020年2月至12月在一家三级医疗中心急诊就诊的COVID-19患者,所有≥18岁、COVID-19实时逆转录聚合酶链反应阳性且就诊时接受CT成像者被纳入。
- 主要结局为CT严重程度评分与生物标志物预测院内死亡的预后能力,各指标预测院内死亡的AUC分别为:D-二聚体0.67(95%CI 0.57-0.77)、CT严重程度评分0.66(95%CI 0.55-0.77)、LDH 0.66(95%CI 0.55-0.77)、Pro-BNP 0.65(95%CI 0.55-0.76)、NLR 0.64(95%CI 0.53-0.75)、肌钙蛋白0.64(95%CI 0.52-0.75)。
- 逐步logistic回归中,与院内死亡显著相关的因素包括:年龄(OR=1.07,95%CI 1.05-1.09)、肥胖(OR=2.02,95%CI 1.25-3.26)、中性粒细胞/淋巴细胞比值(OR=1.02,95%CI 1.01-1.04)、CRP(OR=1.01,95%CI 1.004-1.01)、乳酸脱氢酶(OR=1.003,95%CI 1.001-1.004)和CT严重程度评分(OR=1.17,95%CI 1.12-1.23)。
证据类型、等级与局限
- 证据类型:回顾性病历回顾研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对需要肺部影像的COVID-19患者(如需要ICU入住、生命体征异常和需要机械通气的患者),结果提示获取并计算CT严重程度评分,将其作为预后工具。
- 作者认为,若未进行CT检查,结果提示使用已完成的LDH、CRP或NLR作为COVID-19的预后工具,因为这些生物标志物也被发现在COVID-19患者中具有预后价值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: We aimed to compare the prognostic value of a quantitative CT severity score with several laboratory parameters, particularly C-reactive protein, Procalcitonin, Neutrophil to lymphocyte ratio, D-dimer, ferritin, lactate dehydrogenase, lactate, troponin and B-type Natriuretic Peptide in predicting in-hospital mortality.
METHODS: This was a retrospective chart review study of COVID-19 patients who presented to the Emergency Department of a tertiary care center between February and December 2020. All patients ≥18 years old who tested positive for the COVID-19 real-time reverse transcriptase polymerase chain reaction and underwent CT imaging at presentation were included. The primary outcome was the prognostic ability of CT severity score versus biomarkers in predicting in-hospital mortality.
RESULTS: The AUCs were: D-dimer (AUC: 0.67 95% CI = 0.57-0.77), CT severity score (0.66, 95% CI = 0.55-0.77), LDH (0.66, 95% CI = 0.55-0.77), Pro-BNP (0.65, 95% CI = 0.55-0.76), NLR (0.64, 95% CI = 0.53-0.75) and troponin (0.64, 95% CI = 0.52-0.75). In the stepwise logistic regression, age (OR = 1.07 95% CI = 1.05-1.09), obesity (OR = 2.02 95% CI = 1.25-3.26), neutrophil/lymphocyte ratio (OR = 1.02 95% CI = 1.01-1.04), CRP (OR = 1.01 95% CI = 1.004-1.01), lactate dehydrogenase (OR = 1.003 95% CI = 1.001-1.004) and CT severity score (OR = 1.17 95% CI = 1.12-1.23) were significantly associated with in-hospital mortality.
CONCLUSION: In summary, CT severity score outperformed several biomarkers as a prognostic tool for covid related mortality. In COVID-19 patients requiring lung imaging, such as patients requiring ICU admission, patients with abnormal vital signs and those requiring mechanical ventilation, the results suggest obtaining and calculating the CT severity score to use it as a prognostic tool. If a CT was not performed, the results suggest using LDH, CRP or NLR if already done as prognostic tools in COVID-19 as these biomarkers were also found to be prognostic in COVID-19 patients.
参考来源
- Dagher GA, Ghanem AA, Haidar S, et al. The prognostic value of biomarker levels and chest imaging in patients with COVID-19 presenting to the emergency department. Am J Emerg Med. 2022. PMID: 35772223. doi:10.1016/j.ajem.2022.06.043
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。